US40637H1095
US40637H1095
Halozyme Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 1.396.611.000 | 1.015.324.000 | 37.6% |
| Cost of Revenue | 228.774.000 | 159.417.000 | 43.5% |
| Gross Profit | -- | 855.907.000 | -- |
| 365.244.000 | 304.432.000 | 20.0% | |
| Operating Income | 802.593.000 | 551.475.000 | 45.5% |
| Pretax Income | 466.875.000 | 557.132.000 | 16.2% |
| Net Income Common Stockholders | 316.889.000 | 444.091.000 | 28.6% |
| -- | -- | -- | |
| -- | -- | -- |